Edition:
United Kingdom

vTv Therapeutics Inc (VTVT.OQ)

VTVT.OQ on NASDAQ Stock Exchange Global Market

4.29USD
7:28pm GMT
Change (% chg)

$-0.14 (-3.16%)
Prev Close
$4.43
Open
$4.47
Day's High
$4.63
Day's Low
$4.29
Volume
3,445
Avg. Vol
9,019
52-wk High
$8.04
52-wk Low
$3.63

Chart for

About

vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of orally administered small molecule drug candidates. Its drug candidate for the treatment of Alzheimer's disease (AD) is azeliragon (TTP488), an orally administered, small molecule antagonist targeting... (more)

Overall

Beta: --
Market Cap(Mil.): $204.09
Shares Outstanding(Mil.): 32.81
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 88.65 16.44
EPS (TTM): -- -- --
ROI: -- 2.35 10.62
ROE: -- 2.95 14.20

BRIEF-VTv Therapeutics Entered Into Agreement With MacAndrews & Forbes

* VTV THERAPEUTICS SAYS ON DEC 5, CO ENTERED INTO A LETTER AGREEMENT WITH MACANDREWS & FORBES GROUP LLC - SEC FILING

06 Dec 2017

BRIEF-vTv Therapeutics reports Q3 GAAP loss per share of $0.38

* vTv Therapeutics reports third quarter 2017 financial and operational results

01 Nov 2017

BRIEF-JDRF, VTV Therapeutics collaborate on Phase 2 study of novel treatment for type 1 diabetes

* JDRF and VTV Therapeutics announce collaboration on Phase 2 study of novel treatment for Type 1 diabetes

06 Sep 2017

BRIEF-vTv Therapeutics announces issuance of U.S. patent

* Vtv therapeutics announces issuance of u.s. Patent covering methods of treatment using azeliragon Source text for Eikon: Further company coverage:

03 Aug 2017

BRIEF-vTv Therapeutics Q2 loss per share $0.41

* vTv Therapeutics reports second quarter 2017 financial and operational results

02 Aug 2017

Earnings vs. Estimates